Tigen Pharma SA
|Date:||April 25, 2023|
|Time:||15:30 – 16:15|
Cell and Gene Therapy revolution – how can Switzerland stay at the forefront?
With the US and China running 90% of clinical CGT trials, the EU, UK and Switzerland risk to fall behind. Where are the opportunities and challenges for Switzerland to play an important role in this growing sector? How can the access to novel therapies be improved? How do we bring brilliant research and breakthrough therapies to the patient – what can be different in Switzerland? How can production and supply support, and do we need a more coordinated Swiss way?
Dr. Dorothea Ledergerber, Chief Technical Officer, Tigen
Dr. Karin Blumer, Head of Corporate Affairs CHAT, Bristol Myers Squibb
Andreas Marti (PD, PhD), Responsible Gene Therapy / NCA, Swissmedic, Swiss Agency for Therapeutic Products, Division Advanced Therapy Medicinal Products (ATMP)
Dr. Vera Hirsch, Head of Claims Management Pharmaceuticals and Genetics, Sanitas
Dr. Roch-Philippe Charles, Chief Scientific Officer, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung SAKK
Tigen is a Swiss clinical-stage biotech company in the field of cell therapies to cure cancer. A disruptive catalyst, combining a unique culture with a multidisciplinary set of world-class capabilities and a long-term perspective to the benefit of patients and society.